Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treatment of multiple myeloma and myelodysplastic syndrome. Rituximab ...

• Country None
• organs None
• Specialty None

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma This phase I/II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in tr...

• Country None
• organs None
• Specialty None

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Gi...

• Country None
• organs None
• Specialty None

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.

• Country United States
• organs None
• Specialty None

Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a peri...

• Country None
• organs None
• Specialty None

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned ...

• Country None
• organs None
• Specialty None

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma It has been shown that many patients with lymphoma or chronic lymphocytic leukemia (CLL)have low levels of complement. Several drugs have been approved by the Food and Drug Administration ...

• Country None
• organs None
• Specialty None

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma Obatoclax may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. Bortezomib and obatoclax may stop the growth of cancer cells by blocking some of the enzymes nee...

• Country None
• organs None
• Specialty None